MIRA Pharmaceuticals Inc. saw its stock surge after revealing promising preclinical data for its lead development product, Ketamir-2. This novel oral Ketamine analog achieved a 100% reversal of neuropathic pain in preclinical models, potentially offering a significant advancement in pain management. The company is aiming for human trials by 2025.
MIRA Pharmaceuticals’ oral ketamine analog, Ketamir-2, has demonstrated significant potential in reversing neuropathic pain in a recent preclinical study. The drug showed superior efficacy compared to traditional oral ketamine, achieving complete normalization of pain thresholds in rats. MIRA is optimistic about the potential of Ketamir-2 for treating neuropathic pain and cancer-induced depression, with human trials potentially starting as early as 2025.
Shares of MIRA Pharmaceuticals surged in pre-market trading after announcing a 100% reversal of neuropathic pain in a rat study using its oral Ketamin-2 drug. Other notable pre-market movers include MEDIROM Healthcare, Prestige Wealth, Top KingWin, and Tevogen Bio, with gains attributed to partnerships, acquisitions, and investment news. On the downside, Talis Biomedical, SRIVARU Holding, Draganfly, and ELEVAI Labs experienced significant declines due to regulatory concerns, production updates, and market volatility.
